Shares of OvaScience Inc. (NASDAQ:OVAS) traded down 5.8% on Tuesday . The company traded as low as $5.01 and last traded at $5.01, with a volume of 166,295 shares. The stock had previously closed at $5.32.

A number of analysts have weighed in on the stock. Credit Suisse Group AG reissued a “sell” rating on shares of OvaScience in a report on Tuesday, July 12th. Leerink Swann restated a “hold” rating and set a $7.00 price target (up previously from $6.00) on shares of OvaScience in a research report on Sunday, May 8th. Finally, Oppenheimer Holdings Inc. restated a “hold” rating on shares of OvaScience in a research report on Monday, April 25th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $12.37.

The company’s market capitalization is $148.94 million. The stock’s 50-day moving average price is $5.69 and its 200 day moving average price is $7.32.

OvaScience (NASDAQ:OVAS) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.08. The firm had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.14 million. The company’s revenue was up 630.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.65) EPS. Equities research analysts forecast that OvaScience Inc. will post ($3.14) earnings per share for the current fiscal year.

In other news, CEO Michelle Dipp bought 19,900 shares of OvaScience stock in a transaction that occurred on Tuesday, May 10th. The stock was purchased at an average cost of $7.72 per share, with a total value of $153,628.00. Following the completion of the transaction, the chief executive officer now directly owns 971,921 shares in the company, valued at $7,503,230.12. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard Aldrich bought 36,095 shares of OvaScience stock in a transaction that occurred on Friday, May 13th. The stock was purchased at an average cost of $6.94 per share, with a total value of $250,499.30. Following the completion of the transaction, the director now owns 604,185 shares of the company’s stock, valued at $4,193,043.90. The disclosure for this purchase can be found here.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.